The Science

Four human studies of Akkermansia muciniphila have been published. An observational study in 2016, a 32-person proof-of-concept trial in 2019, a trial in people with type 2 diabetes in 2025, and a 90-person controlled trial of the pasteurised form in May 2026. Almost everything else written about this bacterium comes from mice or from mechanism work in cells. That work matters, and it is not the same thing as evidence in people. This page takes the four human studies in the order they happened and says what each one establishes and where each one stops.

2016 — an observation, not an intervention

The first human signal wasn't a supplement at all. Maria Carlota Dao and colleagues followed 49 overweight adults through a calorie-restricted diet and noticed that those who started with more Akkermansia in their gut tended to show better metabolic markers, including insulin sensitivity, lipids and inflammation, than those who started low (Dao et al., 2016, Gut).

This is an association. It tells us that Akkermansia abundance travels alongside better metabolism. It cannot tell us which causes which, or whether adding Akkermansia would change anything. The study poses the question; it does not answer it.

2019 — the first time anyone gave it to people

Clara Depommier and colleagues in Belgium ran the first interventional trial: 32 overweight, insulin-resistant adults took live A. muciniphila, the pasteurised form, or placebo, daily for three months (Depommier et al., 2019, Nature Medicine). The primary endpoint was safety, and both forms cleared it. The surprise was that the pasteurised, non-living form moved the metabolic markers most, which is the pasteurised paradox we cover separately.

The authors called it small and exploratory, and so do we. Thirty-two people, three months. That is a door opening onto a question. It is also the study that underpinned the EU's authorisation of pasteurised A. muciniphila as a Novel Food in 2022.

2025 — into a clinical population

The field had been waiting for something larger and more specific. In 2025 a trial in Cell Metabolism delivered it: instead of broadly overweight volunteers, it enrolled 58 people with overweight or obesity and type 2 diabetes, a population whose metabolism is by definition already disrupted, and gave half of them a live strain, AKK-WST01, for twelve weeks alongside routine lifestyle guidance (Zhang et al., 2025). That makes it a harder test and a more relevant one.

It missed. Both groups lost weight and both saw HbA1c fall, with no significant difference between them. The result that made the paper interesting came from splitting participants by how much Akkermansia they already carried: those starting low showed good colonisation and significant reductions in weight, fat mass and HbA1c; those starting high showed poor colonisation and no clinical benefit. The authors reproduced the pattern in germ-free mice and framed it as a hypothesis, which is what it is.

Two things follow, and both cut against the easy reading. A subgroup finding in a trial of 58 is hypothesis-generating, not evidence — it tells you what to test next. And the strain was live, where the form authorised in the EU and used in Vekovia is pasteurised; findings about one do not transfer to the other. A trial conducted in people with a condition is not permission to claim a supplement treats that condition. We keep those two ideas apart on purpose.

2026 — the newest trial, and the harder question

In May 2026, Nature Medicine published the study that closes the gap the others left open. Ninety adults with overweight or obesity first lost weight on an eight-week diet, then spent six months eating normally while taking either pasteurised A. muciniphila MucT or placebo (Mount et al., 2026). The supplemented group regained noticeably less: about 1.2 kg versus 3.2 kg over the maintenance period.

This one is easy to oversell, so it is worth reading precisely.

• It tested the harder problem: keeping weight off after a diet, which is where most people actually struggle.
• It used the same pasteurised form the earlier trials and the EU authorisation are built on.
• The effect was real and modest, a difference of roughly 2 kg, in a short trial with a carefully selected group of 90 people.
• It was funded by the company that develops the strain, the same European supplier our bacterium comes from. We tell you that because you should weigh it, and because the independent specialists who reviewed the trial said the honest thing: it is a proof of concept, not a reason to change anyone's medical care, and not an alternative to GLP-1 medicines like semaglutide.

The fair sentence is this. The first controlled trial to test the pasteurised form for weight-loss maintenance found a modest benefit, and the field's own independent commentators called it promising and preliminary in the same breath.

Why the mechanism work sits underneath all of this

None of these human trials float free of biology. Researchers keep testing Akkermansia in metabolic settings because there is a mechanism to test: in 2021, Yoon and colleagues showed that the bacterium secretes a protein, P9, which binds a receptor on intestinal cells and prompts them to release GLP-1, the gut's own appetite-and-glucose hormone (Yoon et al., 2021, Nature Microbiology). That work is mostly in mice. It is also the reason the human metabolic trials exist at all. We unpack it in the GLP-1 explainer.

What the four studies add up to

An observation (2016), a proof of concept (2019), a trial in a clinical population that missed its primary endpoint (2025), a controlled maintenance trial (2026). Each asks more of the bacterium than the one before it, and the record is genuinely mixed rather than a clean upward line — the 2025 trial did not work, and we would rather say so than leave it out. Four studies, none of them large, one of them negative, on an organism the research community itself still describes as a candidate rather than a settled tool.

Pasteurised Akkermansia muciniphila anchors Vekovia · Bilberry, our metabolic-leaning pairing: the bacterium alongside freeze-dried European bilberries, whose polyphenols the broader literature connects to it. We pair them because the science links them, and we describe that science rather than promise you what it will do.

---

References

[^DAO-2016]: Dao MC et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity. Gut 2016. PMID 26100928. DOI 10.1136/gutjnl-2014-308778.

[^DEPOMMIER-2019]: Depommier C et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine 2019. PMID 31263284. DOI 10.1038/s41591-019-0495-2.

[^ZHANG-2025]: Zhang Y et al. Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes. Cell Metabolism 2025. PMID 39879980. DOI 10.1016/j.cmet.2024.12.010.

[^MOUNT-2026]: Mount S et al. Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial. Nature Medicine 2026. PMID 42120725. DOI 10.1038/s41591-026-04394-7. Funded by The Akkermansia Company.

[^YOON-2021]: Yoon HS et al. Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice. Nature Microbiology 2021. PMID 33820962. DOI 10.1038/s41564-021-00880-5.